Statin safety

Statin safety project: open for out-licensing and/or co-depelopment

Scientific background:

Summary of invention:

  • Endogenous substance to inhibit a side effect of statins to reduce endogenous cardioprotection.

IP status:

  • Patented technology (primary filing date May, 2012)

Potential investors and/or co-development partners,

please contact us for further details at

(Please manually type the e-mail address in your e-mail client.)